CR20130359A - Anticuerpos del cea - Google Patents

Anticuerpos del cea

Info

Publication number
CR20130359A
CR20130359A CR20130359A CR20130359A CR20130359A CR 20130359 A CR20130359 A CR 20130359A CR 20130359 A CR20130359 A CR 20130359A CR 20130359 A CR20130359 A CR 20130359A CR 20130359 A CR20130359 A CR 20130359A
Authority
CR
Costa Rica
Prior art keywords
cea antibodies
abms
cea
membranes
bind
Prior art date
Application number
CR20130359A
Other languages
English (en)
Inventor
Thomas U Hofer
Ralf Hosse
Ekkehard Moessner
Pablo Umana
Original Assignee
Roche Glycart Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Glycart Ag filed Critical Roche Glycart Ag
Publication of CR20130359A publication Critical patent/CR20130359A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención proporciona moléculas de unión a antígeno (ABMs) que se unen a CEA unido a membranas, incluyendo ABMS con porpiedades terapéuticas mejoradas, y métodos de utilización de las mismas
CR20130359A 2011-03-02 2013-07-23 Anticuerpos del cea CR20130359A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11156665 2011-03-02

Publications (1)

Publication Number Publication Date
CR20130359A true CR20130359A (es) 2013-11-11

Family

ID=45811481

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130359A CR20130359A (es) 2011-03-02 2013-07-23 Anticuerpos del cea

Country Status (35)

Country Link
US (7) US8642742B2 (es)
EP (2) EP3333193A1 (es)
JP (1) JP6046642B2 (es)
KR (1) KR101981342B1 (es)
CN (1) CN103403029B (es)
AR (1) AR085591A1 (es)
AU (1) AU2012222463B9 (es)
BR (1) BR112013021460B1 (es)
CA (1) CA2827722C (es)
CL (1) CL2013002203A1 (es)
CO (1) CO6781491A2 (es)
CR (1) CR20130359A (es)
DK (1) DK2681244T3 (es)
EA (1) EA029300B1 (es)
EC (1) ECSP13012859A (es)
ES (1) ES2657856T3 (es)
HK (1) HK1187056A1 (es)
HR (1) HRP20180147T1 (es)
HU (1) HUE036229T2 (es)
IL (1) IL227482B (es)
LT (1) LT2681244T (es)
MA (1) MA34927B1 (es)
MX (1) MX347590B (es)
MY (1) MY164647A (es)
NO (1) NO2681244T3 (es)
PE (1) PE20141017A1 (es)
PL (1) PL2681244T3 (es)
PT (1) PT2681244T (es)
RS (1) RS56793B1 (es)
SG (1) SG192972A1 (es)
SI (1) SI2681244T1 (es)
TW (1) TWI553016B (es)
UA (1) UA115030C2 (es)
WO (1) WO2012117002A1 (es)
ZA (1) ZA201305323B (es)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2770174A1 (en) * 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
MY190604A (en) 2011-02-10 2022-04-27 Roche Glycart Ag Mutant interleukin-2 polypeptides
LT2681244T (lt) 2011-03-02 2018-02-12 Roche Glycart Ag Cea antikūnai
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
CN104520324A (zh) 2012-02-24 2015-04-15 施特姆森特Rx股份有限公司 Dll3调节剂及其使用方法
DK3199552T3 (da) * 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
US11059910B2 (en) 2012-12-03 2021-07-13 Novimmune Sa Anti-CD47 antibodies and methods of use thereof
HUE043851T2 (hu) 2013-02-22 2019-09-30 Abbvie Stemcentrx Llc Anti-DLL3-antitest-PBD konjugátumok és alkalmazásuk
JP2014161283A (ja) * 2013-02-26 2014-09-08 Shizuoka Prefecture Ｃｅａｃａｍ５遺伝子のスプライシングバリアント
WO2014131711A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
ES2775207T3 (es) * 2013-02-26 2020-07-24 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA
EP3892294A1 (en) 2013-08-28 2021-10-13 AbbVie Stemcentrx LLC Site-specific antibody conjugation methods and compositions
JP2016538318A (ja) 2013-08-28 2016-12-08 ステムセントリックス， インコーポレイテッド 新規ｓｅｚ６モジュレーターおよび使用方法
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
AR100271A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Compuestos de vegfr2 / ang2
PL3177643T3 (pl) 2014-08-04 2019-09-30 F.Hoffmann-La Roche Ag Dwuswoiste cząsteczki wiążące antygen aktywujące komórki T
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
EP3356410B1 (en) 2015-10-02 2021-10-20 F. Hoffmann-La Roche AG Bispecific anti-ceaxcd3 t cell activating antigen binding molecules
CN106065032B (zh) * 2015-11-30 2019-07-09 成都金昆生物科技有限公司 一新型蛋白结合片段
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
EP3178848A1 (en) * 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
RU2652955C1 (ru) * 2015-12-24 2018-05-03 Федеральное государственное бюджетное учреждение "Российский научный центр рентгенорадиологии" Министерства здравоохранения российской федерации (ФГБУ "РНЦРР" Минздрава России) Мономолекулярный химерный т-клеточный рецептор к раково-эмбриональному антигену
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
JP2019522960A (ja) 2016-04-21 2019-08-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｂｍｐｒ１ｂ抗体及び使用方法
MA46851A (fr) 2016-11-18 2019-09-25 Astellas Pharma Inc NOUVEAU FRAGMENT Fab D'ANTICORPS ANTI-MUC1 HUMAIN
KR20190136076A (ko) 2017-04-13 2019-12-09 에프. 호프만-라 로슈 아게 암 치료 방법에 사용하기 위한 인터루킨-2 면역접합체, cd40 작용제 및 임의적인 pd-1 축 결합 길항제
TWI795415B (zh) 2017-07-07 2023-03-11 日商安斯泰來製藥股份有限公司 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段
CN108219004A (zh) * 2018-02-08 2018-06-29 吉林省拓华生物科技有限公司 双特异嵌合抗原受体修饰的t细胞、其制备方法及用途
JP7515412B2 (ja) 2018-03-09 2024-07-12 アスクジーン・ファーマ・インコーポレイテッド 新規のサイトカインプロドラッグ
KR20210029158A (ko) 2018-06-03 2021-03-15 람카프 바이오 베타 엘티디. Ceacam5 및 cd47에 대한 이중특이성 항체
SG11202103670XA (en) 2018-10-10 2021-05-28 Astellas Pharma Inc Pharmaceutical composition containing tagged site-antihuman antibody fab fragment complex
CN113646332B (zh) * 2019-03-15 2024-08-23 公益财团法人癌研究会 抗平足蛋白抗体
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
CA3142887A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
WO2020259550A1 (zh) 2019-06-26 2020-12-30 江苏恒瑞医药股份有限公司 抗cea抗体及其应用
AR119382A1 (es) 2019-07-12 2021-12-15 Hoffmann La Roche Anticuerpos de pre-direccionamiento y métodos de uso
EP4025254A1 (en) 2019-09-03 2022-07-13 Bolt Biotherapeutics, Inc. Aminoquinoline compounds, immunoconjugates, and uses thereof
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
EP4034551A1 (en) 2019-09-28 2022-08-03 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
AU2020359446A1 (en) 2019-09-30 2022-04-21 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
JP2022553702A (ja) 2019-10-25 2022-12-26 ボルト バイオセラピューティクス、インコーポレーテッド チエノアゼピン、イムノコンジュゲート、及びそれらの使用
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP2023524271A (ja) 2020-05-08 2023-06-09 ボルト バイオセラピューティクス、インコーポレーテッド エラスターゼ－基質ペプチドリンカーイムノコンジュゲート、及びそれらの使用
BR112023000204A2 (pt) 2020-07-10 2023-01-31 Hoffmann La Roche Conjunto de anticorpos, conjunto de ácidos nucleicos, vetor de expressão, célula hospedeira, métodos de pré-direcionamento de radioimunoterapia e direcionamento de um radioisótopo, ligante peptídico, proteína de múltiplos domínios e usos
MX2023001679A (es) 2020-08-13 2023-02-22 Bolt Biotherapeutics Inc Inmunoconjugados de pirazolazepina y usos de estos.
AU2021329375A1 (en) 2020-08-20 2023-04-20 A2 Biotherapeutics, Inc. Compositions and methods for treating ceacam positive cancers
EP4100028A4 (en) 2020-08-20 2023-07-26 A2 Biotherapeutics, Inc. COMPOSITIONS AND METHODS FOR THE TREATMENT OF MESOTHELIN-POSITIVE CANCERS
CA3200051A1 (en) 2020-12-11 2022-06-16 Shelley Erin ACKERMAN Anti-cea immunoconjugates, and uses thereof
US20220195066A1 (en) 2020-12-11 2022-06-23 Bolt Biotherapeutics, Inc. Anti-cea immunoconjugates, and uses thereof
WO2022133042A1 (en) * 2020-12-18 2022-06-23 Bioardis, Llc Cea5 binding molecules and uses thereof
HUE065728T2 (hu) 2020-12-18 2024-06-28 Lamkap Bio Beta Ag CEACAM5 és CD47 elleni bispecifikus antitestek
WO2022152656A1 (en) 2021-01-12 2022-07-21 F. Hoffmann-La Roche Ag Split antibodies which bind to cancer cells and target radionuclides to said cells
MX2023008083A (es) 2021-01-13 2023-07-13 Hoffmann La Roche Tratamiento conjunto.
CN112557662B (zh) * 2021-02-22 2021-07-06 和卓生物科技（上海）有限公司 一种结直肠癌检测试剂盒
EP4313161A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
EP4313162A1 (en) 2021-03-26 2024-02-07 Bolt Biotherapeutics, Inc. 2-amino-4-carboxamide-benzazepine immunoconjugates, and uses thereof
CN115819596A (zh) * 2021-09-17 2023-03-21 优迈生物科技(连云港)有限公司 一种靶向人ceacam5/6的抗体、制备方法和应用
IL314916A (en) 2022-03-07 2024-10-01 Novimmune Sa Bispecific CD28 antibodies for targeted T cell activation
AU2023237620A1 (en) 2022-03-23 2024-08-29 Synaffix B.V. Antibody-conjugates for targeting of tumours expressing carcinoembyronic antigen
WO2024110905A1 (en) 2022-11-24 2024-05-30 Beigene, Ltd. Anti-cea antibody drug conjugates and methods of use

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5872215A (en) 1991-12-02 1999-02-16 Medical Research Council Specific binding members, materials and methods
GB9317423D0 (en) * 1993-08-21 1993-10-06 Imp Cancer Res Tech Monoclonal antibodies
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
CA2321947A1 (en) * 1998-02-25 1999-09-02 The Dow Chemical Company High affinity humanized anti-cea monoclonal antibodies
DK2180007T4 (da) 1998-04-20 2017-11-27 Roche Glycart Ag Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP2275541B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2417415C (en) 2000-07-31 2012-10-09 Biolex, Inc. Expression of biologically active polypeptides in duckweed
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
NZ592087A (en) 2001-08-03 2012-11-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
AU2002337935B2 (en) 2001-10-25 2008-05-01 Genentech, Inc. Glycoprotein compositions
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US8932825B2 (en) 2001-12-27 2015-01-13 Glycofi Inc. Method to engineer mammalian-type carbohydrate structures
US7432063B2 (en) 2002-02-14 2008-10-07 Kalobios Pharmaceuticals, Inc. Methods for affinity maturation
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EP2319935B1 (en) 2002-03-19 2016-04-27 Stichting Dienst Landbouwkundig Onderzoek GnTIII (UDP-N-acetylglucosamine:Beta -D mannoside Beta (1,4)-N-acetylglucosaminyltransferase III) expression in plants.
JP4832719B2 (ja) 2002-04-09 2011-12-07 協和発酵キリン株式会社 ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
EP1498490A4 (en) 2002-04-09 2006-11-29 Kyowa Hakko Kogyo Kk PROCESS FOR PREPARING ANTIBODY COMPOSITION
WO2003085107A1 (fr) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Cellules à génome modifié
EP1498491A4 (en) 2002-04-09 2006-12-13 Kyowa Hakko Kogyo Kk METHOD FOR INCREASING THE ACTIVITY OF AN ANTIBODY COMPOSITION FOR BINDING TO THE FC GAMMA RECEPTOR IIIA
US7232888B2 (en) 2002-07-01 2007-06-19 Massachusetts Institute Of Technology Antibodies against tumor surface antigens
AU2003270152A1 (en) 2002-09-12 2004-04-30 Greenovation Biotech Gmbh Protein production method
US7781197B2 (en) 2002-12-20 2010-08-24 Greenovation Biotech Gmbh Transformed bryophyte cell having disrupted endogenous alpha 1,3-fucosyl and beta 1,2-xylosyl transferase encoding nucleotide sequences for the production of heterologous glycosylated proteins
EP2368578A1 (en) 2003-01-09 2011-09-28 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
KR101292000B1 (ko) * 2003-01-22 2013-08-01 로슈 글리카트 아게 융합 구성체와 Ｆｃ 수용체 결합 친화도 및 이펙터 기능이증가된 항체를 생성하기 위한 이의 용도
WO2004101790A1 (en) 2003-05-14 2004-11-25 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
EP2471813B1 (en) * 2004-07-15 2014-12-31 Xencor, Inc. Optimized Fc variants
CA2596925C (en) * 2005-02-08 2017-07-04 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Method for improving expression level and stability of antibody
CA2770174A1 (en) * 2009-08-31 2011-03-03 Roche Glycart Ag Affinity-matured humanized anti cea monoclonal antibodies
AU2010303142B2 (en) * 2009-09-29 2013-05-09 Roche Glycart Ag Bispecific death receptor agonistic antibodies
MY190604A (en) * 2011-02-10 2022-04-27 Roche Glycart Ag Mutant interleukin-2 polypeptides
LT2681244T (lt) * 2011-03-02 2018-02-12 Roche Glycart Ag Cea antikūnai
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2848732T3 (es) * 2012-08-07 2021-08-11 Roche Glycart Ag Inmunoterapia mejorada
WO2014131711A1 (en) * 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
ES2775207T3 (es) * 2013-02-26 2020-07-24 Roche Glycart Ag Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas específicas para CD3 y CEA
HUE047806T2 (hu) * 2014-08-29 2020-05-28 Hoffmann La Roche Kombinációs kezelés tumort célzó IL-2-variáns immuncitokinekkel és humán PD-L1 elleni antitestekkel

Also Published As

Publication number Publication date
EP3333193A1 (en) 2018-06-13
US20230365711A1 (en) 2023-11-16
AU2012222463A1 (en) 2013-07-25
KR101981342B1 (ko) 2019-05-22
UA115030C2 (uk) 2017-09-11
CA2827722C (en) 2020-05-12
PE20141017A1 (es) 2014-08-25
BR112013021460A2 (pt) 2016-10-25
ES2657856T3 (es) 2018-03-07
JP2014509200A (ja) 2014-04-17
CN103403029A (zh) 2013-11-20
TWI553016B (zh) 2016-10-11
EA201300978A1 (ru) 2014-02-28
ECSP13012859A (es) 2013-10-31
MX2013009664A (es) 2013-10-30
AU2012222463B2 (en) 2017-05-04
JP6046642B2 (ja) 2016-12-21
AU2012222463B9 (en) 2017-05-25
MX347590B (es) 2017-05-03
IL227482A0 (en) 2013-09-30
SG192972A1 (en) 2013-09-30
EA029300B1 (ru) 2018-03-30
KR20140021588A (ko) 2014-02-20
BR112013021460B1 (pt) 2022-12-20
MY164647A (en) 2018-01-30
US20220002441A1 (en) 2022-01-06
ZA201305323B (en) 2016-02-24
SI2681244T1 (en) 2018-03-30
EP2681244A1 (en) 2014-01-08
US20140212408A1 (en) 2014-07-31
CA2827722A1 (en) 2012-09-07
US20180079827A1 (en) 2018-03-22
PT2681244T (pt) 2018-01-24
PL2681244T3 (pl) 2018-04-30
EP2681244B1 (en) 2017-11-29
CO6781491A2 (es) 2013-10-31
US20190185583A1 (en) 2019-06-20
US20160229923A1 (en) 2016-08-11
CL2013002203A1 (es) 2013-12-06
US9206260B2 (en) 2015-12-08
HUE036229T2 (hu) 2018-06-28
US8642742B2 (en) 2014-02-04
HK1187056A1 (zh) 2014-03-28
NZ614125A (en) 2015-07-31
HRP20180147T1 (hr) 2018-02-23
US20120251529A1 (en) 2012-10-04
NO2681244T3 (es) 2018-04-28
CN103403029B (zh) 2015-11-25
DK2681244T3 (da) 2018-01-29
RS56793B1 (sr) 2018-04-30
TW201249873A (en) 2012-12-16
LT2681244T (lt) 2018-02-12
AR085591A1 (es) 2013-10-16
AU2012222463A8 (en) 2013-09-05
IL227482B (en) 2019-10-31
WO2012117002A1 (en) 2012-09-07
MA34927B1 (fr) 2014-02-01

Similar Documents

Publication Publication Date Title
CR20130359A (es) Anticuerpos del cea
CY1123079T1 (el) Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων
CY1121862T1 (el) Αντισωματα anti-phf-tau και χρησεις αυτων
CY1123550T1 (el) Διπλοειδικα egfr/c-met αντισωματα
CY1121911T1 (el) Cd47 αντισωματα και μεθοδοι χρησης αυτων
CL2017000888A1 (es) Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
CL2015002756A1 (es) Moléculas fc biespecíficas
CO7010784A2 (es) Moléculas que son anticuerpos con especificidad por ox40 humano
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EA201491947A1 (ru) Антитела и иммуноконъюгаты к ly6e и способы применения
CO7400860A2 (es) Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos
EA201300819A1 (ru) Молекулы антител, которые связываются с il-17a и il-17f
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
BR112017004614A2 (pt) terapias de combinação com anticorpos anti-cd38
CY1118885T1 (el) Συνθετικες πεπτιδογλυκανες που δεσμευουν υαλουρονικο οξυ, παρασκευη, και μεθοδοι χρησης
DK3177643T3 (da) Bispecifikke T-celle-aktiverende antigenbindende molekyler
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
DK3156416T3 (da) Sekvenssymmetriske modificerede bispecifikke igg4-antistoffer
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CU20160118A7 (es) Moléculas de anticuerpo que se unen a tim-3
ECSP14028523A (es) Moléculas de anticuerpo anti-gcc y uso de las mismas
GT201400045A (es) Anticuerpo anti-abtcr
EA201201016A1 (ru) Антидоты антикоагулянтов
EA201491357A1 (ru) Анти-lrp5 антитела и способы их применения
EP3019532A4 (en) CERTAIN IMPROVED HUMAN BISPECIFIC EGFRvIII ANTIBODY ENGAGING MOLECULES